Please login to the form below

Not currently logged in
Email:
Password:

phase 2 trial

This page shows the latest phase 2 trial news and features for those working in and with pharma, biotech and healthcare.

Celltrion’s investigational mAb cuts COVID-19 recovery time

Celltrion’s investigational mAb cuts COVID-19 recovery time

Our top-line data from the global phase 2/3 clinical trial has demonstrated that CT-P59 is effective for the treatment of COVID-19 in mild-to-moderate patients and ... In September, Celltrion also announced interim results from a phase 1 clinical trial

Latest news

More from news
Approximately 0 fully matching, plus 220 partially matching documents found.

Latest Intelligence

  • Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy

    Selumetinib was given ‘breakthrough therapy’ status and rapidly green-lit by the FDA last month (April) following a promising National Cancer Institute (NCI) Cancer Therapy Evaluation Program sponsored phase 2 trial. ... With the latest phase 2 data,

  • Developing a COVID-19 vaccine Developing a COVID-19 vaccine

    To win approval for public use, a larger phase 2 trial is need, which Moderna says is already in the planning stages and could start within a few months. ... The EMA has acknowledged the impact the pandemic may have on clinical trails and trial

  • Rethinking trials: the pros and cons of protocol amendments Rethinking trials: the pros and cons of protocol amendments

    AstraZeneca spokesman Matthew Kent said: “The BICLA was chosen as the primary endpoint for TULIP 2, following a full evaluation of the previous phase e trial TULIP 1, which did not ... The patient sampling size increases, as well, increasing the

  • Integrating patient reported outcomes into clinical trials Integrating patient reported outcomes into clinical trials

    MyoKardia is gathering PROs in its phase 2 hypertrophic cardiomyopathy trial. ... Cara Therapeutics put two questionnaires about itching at the centre of its phase 3 pruritus trial.

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    In phase 2, the figure fell to less than one-third. Data on the early-stage pipeline is lacking but anecdotal evidence suggests it is more diverse still. ... AbbVie is testing its anti-tau antibody ABBV-8E12 in a phase 2 trial, while Biogen has links to

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Infographics